JeanMarie Guenot is a successful business executive who has been working in the biotechnology and pharmaceutical industry for more than 20 years. Throughout her career, she has interacted with both private, and public pharmaceutical companies. She has also worked for business development, venture capital, and commercial development companies. Dr. Guenot is renowned for building an ophthalmic start-up known as SKS Ocular. The start-up focused on developing ocular drug delivery solutions. It also focused on ocular inflammation, macular degeneration, and glaucoma therapeutics. Her experience in creating and managing companies was the contributing factor to SKS Ocular’s success. It’s also part of why Jeanmarie Guenot was recognized by BioSpace as one of the 10 Hottest Bay Area Tech Startups.
Shanghai-based Hoffmann-La Roche appointed her as the business advisor for one year. She began her professional career as a venture capital investments manager for Atlas Venture. JeanMarie Guenot also served on the company’s board of directors at the same time. Her scientific career commenced after she was employed as the principal scientist for Hoffmann-La-Roche’s R&D.
As a physical and medicinal chemistry graduate, she focused on several semi-empirical and quantum mechanical methods. She applied these methods in drug design, NMR refinement, and protein structure prediction. Before working for the company, she has served as PDL BioPharma’s VP of Corporate & Business Development. She also facilitated alliance management, mergers, and acquisitions for R&D, which is a subsidiary of PDL BioPharma. One of her notable career achievements is when she advocated for the commercialization and development of Idec-PDL50:50. The drug was developed for autoimmune diseases and Phase 2 cancer. This work earned her an Innovative Bio-Partnering Award from the BioBusiness Network.
In 2006, the Licensing Executives Society awarded her a Deal of Distinction for her pharmaceutical innovations. Consequently, in 2008, she successfully acquired the product rights of her innovation known as PDL-Biogen. The product rights stated that she developed the drug in partnership with an ophthalmology company known as Ophthotech.
Executive Committee Roles
PDL appointed her as a member of its Portfolio Management Committee and Executive Team. Her roles involved providing strategic planning insights on the commercialization of Biogen Idec-PDL. She served in PDL’s Portfolio Management Committee because of her expertise on ophthalmic, cardiovascular, and autoimmune diseases. Read more about what she is trying to accomplish with Jeanmarie’s agreement between Amphivena and Janssen to develop new cancer fighting biotechnology.